Post hoc analysis of atogepant 60 mg arms in ELEVATE (episodic) and PROGRESS (chronic migraine): of month-1 ≥50% responders, 61.3% and 74.2% sustained response through months 2–3. Interim OLE: of month-4 responders, 83.4% and 88.5% sustained ≥50% response at month 12.
Secondary analysisn = 407
Cho et al. Sustained response to atogepant in episodic and chronic migraine: Post-hoc analyses of ELEVATE and PROGRESS, and their open-label extension